drugset / Trial / NCT02402660

Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

NCT02402660 ↗

Phase 2 Enrolling by invitation 160 enrolled Alkeus Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old. Funding Source - FDA OOPD

Timeline

Start
2015-08
Primary completion
2026-06-30
Completion
2026-11-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject ALK-001 Small molecule — Oral